Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
Background The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is extremely poor and the recurrence rate after curative operation is very high. There is no standard treatment to prevent recurrence of ICC. In this study, we investigated the clinical utilization of a dendritic cell va...
Gespeichert in:
| Veröffentlicht in: | Journal of hepato-biliary-pancreatic sciences 2012-03, Vol.19 (2), p.171-178 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 2 |
| container_start_page | 171 |
| container_title | Journal of hepato-biliary-pancreatic sciences |
| container_volume | 19 |
| creator | Shimizu, Koichi Kotera, Yoshihito Aruga, Atsushi Takeshita, Nobuhiro Takasaki, Ken Yamamoto, Masakazu |
| description | Background
The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is extremely poor and the recurrence rate after curative operation is very high. There is no standard treatment to prevent recurrence of ICC. In this study, we investigated the clinical utilization of a dendritic cell vaccine plus activated T-cell transfer in an adjuvant setting for postoperative ICC.
Methods
36 patients with ICC were vaccinated at least 3 times with autologous tumor lysate pulsed dendritic cells plus ex-vivo activated T-cell transfer. The 5-year progression-free survival (PFS) and overall survival (OS) were measured and compared with those of 26 patients who received the curative operation alone as a concurrent control. The registration number was UMIN000005820.
Results
The median PFS and OS were 18.3 and 31.9 months in the patients receiving adjuvant immunotherapy and 7.7 and 17.4 months in the group receiving surgery alone (
p
= 0.005 and 0.022, respectively). In the treated group, patients whose skin reactions were 3 cm or more at the vaccine site showed dramatically better prognosis (PFS
p
|
| doi_str_mv | 10.1007/s00534-011-0437-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_917155859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>917155859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4811-84217d37db719c3f8234d5c17309d125fdb8f8e5cf2c7faa7ef0a95e161e160f3</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhiMEolXpA3BBljhwCnjiOHaOdAUtpQIkisrN8jrjrkvWDnbSsn2GPjReUlaIA1iybM18_--x_qJ4CvQlUCpeJUo5q0sKUNKaiXLzoNgH2ciyaWX1cHcX9V5xmNIVzYsBaxl9XOxVIEVdCblf3C16553RPZlG17tbPbrgSbBkCGkMA8ZcuEbSoe-iG50hBvueXGtjnEcy9FMi2mREj9iR8_JXd4zaJ4uROE-GrEc_JnLjxlUu5N4Kt8XstAq99pcuGB2zW1jrJ8Ujq_uEh_fnQfHl7ZvzxUl59vH43eL1WWlqmb8r6wpEx0S3FNAaZmXF6o4bEIy2HVTcdktpJXJjKyOs1gIt1S1HaCBvatlB8WL2HWL4PmEa1dql7ejaY5iSakEA55K3mXz-F3kVpujzcCozwCVr6jpTMFMmhpQiWjVEt9Zxo4CqbVhqDkvlsNQ2LLXJmmf3ztNyjd1O8TuaDIgZuHE9bv7vqE5Pjj6BbCErq1mZsshfYvxj6H_MU84il0b8sXtOx2-qEUxwdfHhWAGwz6dH77-qC_YTOpTCYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1711583644</pqid></control><display><type>article</type><title>Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Shimizu, Koichi ; Kotera, Yoshihito ; Aruga, Atsushi ; Takeshita, Nobuhiro ; Takasaki, Ken ; Yamamoto, Masakazu</creator><creatorcontrib>Shimizu, Koichi ; Kotera, Yoshihito ; Aruga, Atsushi ; Takeshita, Nobuhiro ; Takasaki, Ken ; Yamamoto, Masakazu</creatorcontrib><description>Background
The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is extremely poor and the recurrence rate after curative operation is very high. There is no standard treatment to prevent recurrence of ICC. In this study, we investigated the clinical utilization of a dendritic cell vaccine plus activated T-cell transfer in an adjuvant setting for postoperative ICC.
Methods
36 patients with ICC were vaccinated at least 3 times with autologous tumor lysate pulsed dendritic cells plus ex-vivo activated T-cell transfer. The 5-year progression-free survival (PFS) and overall survival (OS) were measured and compared with those of 26 patients who received the curative operation alone as a concurrent control. The registration number was UMIN000005820.
Results
The median PFS and OS were 18.3 and 31.9 months in the patients receiving adjuvant immunotherapy and 7.7 and 17.4 months in the group receiving surgery alone (
p
= 0.005 and 0.022, respectively). In the treated group, patients whose skin reactions were 3 cm or more at the vaccine site showed dramatically better prognosis (PFS
p
< 0.001, OS
p
= 0.001).
Conclusions
A postoperative dendritic cell vaccine plus activated T-cell transfer would be a feasible and effective treatment for preventing recurrence and achieving long-term survival in ICC patients.</description><identifier>ISSN: 1868-6974</identifier><identifier>EISSN: 1868-6982</identifier><identifier>DOI: 10.1007/s00534-011-0437-y</identifier><identifier>PMID: 21874278</identifier><language>eng</language><publisher>Japan: Blackwell Publishing Ltd</publisher><subject>Abdominal Surgery ; adjuvant therapy ; Adoptive Transfer - methods ; Aged ; Bile Duct Neoplasms - immunology ; Bile Duct Neoplasms - therapy ; Bile Ducts, Intrahepatic ; cancer vaccine ; Cancer Vaccines - therapeutic use ; Cholangiocarcinoma - immunology ; Cholangiocarcinoma - therapy ; dendritic cell ; Dendritic cells ; Dendritic Cells - immunology ; Female ; Gastroenterology ; Hepatology ; Humans ; immunotherapy ; intrahepatic cholangiocarcinoma ; Liver Neoplasms - immunology ; Liver Neoplasms - therapy ; Lymphocyte Activation ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article ; Ovarian cancer ; Postoperative Care - utilization ; Prospective Studies ; recurrence ; Surgical Oncology ; T-Lymphocytes - immunology ; Treatment Outcome ; Vaccines</subject><ispartof>Journal of hepato-biliary-pancreatic sciences, 2012-03, Vol.19 (2), p.171-178</ispartof><rights>Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer 2011</rights><rights>2012 Japanese Society of Hepato‐Biliary‐Pancreatic Surgery</rights><rights>2012 Japanese Society of Hepato-Biliary-Pancreatic Surgery</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4811-84217d37db719c3f8234d5c17309d125fdb8f8e5cf2c7faa7ef0a95e161e160f3</citedby><cites>FETCH-LOGICAL-c4811-84217d37db719c3f8234d5c17309d125fdb8f8e5cf2c7faa7ef0a95e161e160f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1007%2Fs00534-011-0437-y$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1007%2Fs00534-011-0437-y$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21874278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimizu, Koichi</creatorcontrib><creatorcontrib>Kotera, Yoshihito</creatorcontrib><creatorcontrib>Aruga, Atsushi</creatorcontrib><creatorcontrib>Takeshita, Nobuhiro</creatorcontrib><creatorcontrib>Takasaki, Ken</creatorcontrib><creatorcontrib>Yamamoto, Masakazu</creatorcontrib><title>Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma</title><title>Journal of hepato-biliary-pancreatic sciences</title><addtitle>J Hepatobiliary Pancreat Sci</addtitle><addtitle>Journal of Hepato-Biliary-Pancreatic Sciences</addtitle><description>Background
The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is extremely poor and the recurrence rate after curative operation is very high. There is no standard treatment to prevent recurrence of ICC. In this study, we investigated the clinical utilization of a dendritic cell vaccine plus activated T-cell transfer in an adjuvant setting for postoperative ICC.
Methods
36 patients with ICC were vaccinated at least 3 times with autologous tumor lysate pulsed dendritic cells plus ex-vivo activated T-cell transfer. The 5-year progression-free survival (PFS) and overall survival (OS) were measured and compared with those of 26 patients who received the curative operation alone as a concurrent control. The registration number was UMIN000005820.
Results
The median PFS and OS were 18.3 and 31.9 months in the patients receiving adjuvant immunotherapy and 7.7 and 17.4 months in the group receiving surgery alone (
p
= 0.005 and 0.022, respectively). In the treated group, patients whose skin reactions were 3 cm or more at the vaccine site showed dramatically better prognosis (PFS
p
< 0.001, OS
p
= 0.001).
Conclusions
A postoperative dendritic cell vaccine plus activated T-cell transfer would be a feasible and effective treatment for preventing recurrence and achieving long-term survival in ICC patients.</description><subject>Abdominal Surgery</subject><subject>adjuvant therapy</subject><subject>Adoptive Transfer - methods</subject><subject>Aged</subject><subject>Bile Duct Neoplasms - immunology</subject><subject>Bile Duct Neoplasms - therapy</subject><subject>Bile Ducts, Intrahepatic</subject><subject>cancer vaccine</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Cholangiocarcinoma - immunology</subject><subject>Cholangiocarcinoma - therapy</subject><subject>dendritic cell</subject><subject>Dendritic cells</subject><subject>Dendritic Cells - immunology</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>immunotherapy</subject><subject>intrahepatic cholangiocarcinoma</subject><subject>Liver Neoplasms - immunology</subject><subject>Liver Neoplasms - therapy</subject><subject>Lymphocyte Activation</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Ovarian cancer</subject><subject>Postoperative Care - utilization</subject><subject>Prospective Studies</subject><subject>recurrence</subject><subject>Surgical Oncology</subject><subject>T-Lymphocytes - immunology</subject><subject>Treatment Outcome</subject><subject>Vaccines</subject><issn>1868-6974</issn><issn>1868-6982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhiMEolXpA3BBljhwCnjiOHaOdAUtpQIkisrN8jrjrkvWDnbSsn2GPjReUlaIA1iybM18_--x_qJ4CvQlUCpeJUo5q0sKUNKaiXLzoNgH2ciyaWX1cHcX9V5xmNIVzYsBaxl9XOxVIEVdCblf3C16553RPZlG17tbPbrgSbBkCGkMA8ZcuEbSoe-iG50hBvueXGtjnEcy9FMi2mREj9iR8_JXd4zaJ4uROE-GrEc_JnLjxlUu5N4Kt8XstAq99pcuGB2zW1jrJ8Ujq_uEh_fnQfHl7ZvzxUl59vH43eL1WWlqmb8r6wpEx0S3FNAaZmXF6o4bEIy2HVTcdktpJXJjKyOs1gIt1S1HaCBvatlB8WL2HWL4PmEa1dql7ejaY5iSakEA55K3mXz-F3kVpujzcCozwCVr6jpTMFMmhpQiWjVEt9Zxo4CqbVhqDkvlsNQ2LLXJmmf3ztNyjd1O8TuaDIgZuHE9bv7vqE5Pjj6BbCErq1mZsshfYvxj6H_MU84il0b8sXtOx2-qEUxwdfHhWAGwz6dH77-qC_YTOpTCYA</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Shimizu, Koichi</creator><creator>Kotera, Yoshihito</creator><creator>Aruga, Atsushi</creator><creator>Takeshita, Nobuhiro</creator><creator>Takasaki, Ken</creator><creator>Yamamoto, Masakazu</creator><general>Blackwell Publishing Ltd</general><general>Springer Japan</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma</title><author>Shimizu, Koichi ; Kotera, Yoshihito ; Aruga, Atsushi ; Takeshita, Nobuhiro ; Takasaki, Ken ; Yamamoto, Masakazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4811-84217d37db719c3f8234d5c17309d125fdb8f8e5cf2c7faa7ef0a95e161e160f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abdominal Surgery</topic><topic>adjuvant therapy</topic><topic>Adoptive Transfer - methods</topic><topic>Aged</topic><topic>Bile Duct Neoplasms - immunology</topic><topic>Bile Duct Neoplasms - therapy</topic><topic>Bile Ducts, Intrahepatic</topic><topic>cancer vaccine</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Cholangiocarcinoma - immunology</topic><topic>Cholangiocarcinoma - therapy</topic><topic>dendritic cell</topic><topic>Dendritic cells</topic><topic>Dendritic Cells - immunology</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>immunotherapy</topic><topic>intrahepatic cholangiocarcinoma</topic><topic>Liver Neoplasms - immunology</topic><topic>Liver Neoplasms - therapy</topic><topic>Lymphocyte Activation</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Ovarian cancer</topic><topic>Postoperative Care - utilization</topic><topic>Prospective Studies</topic><topic>recurrence</topic><topic>Surgical Oncology</topic><topic>T-Lymphocytes - immunology</topic><topic>Treatment Outcome</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimizu, Koichi</creatorcontrib><creatorcontrib>Kotera, Yoshihito</creatorcontrib><creatorcontrib>Aruga, Atsushi</creatorcontrib><creatorcontrib>Takeshita, Nobuhiro</creatorcontrib><creatorcontrib>Takasaki, Ken</creatorcontrib><creatorcontrib>Yamamoto, Masakazu</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepato-biliary-pancreatic sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimizu, Koichi</au><au>Kotera, Yoshihito</au><au>Aruga, Atsushi</au><au>Takeshita, Nobuhiro</au><au>Takasaki, Ken</au><au>Yamamoto, Masakazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma</atitle><jtitle>Journal of hepato-biliary-pancreatic sciences</jtitle><stitle>J Hepatobiliary Pancreat Sci</stitle><addtitle>Journal of Hepato-Biliary-Pancreatic Sciences</addtitle><date>2012-03</date><risdate>2012</risdate><volume>19</volume><issue>2</issue><spage>171</spage><epage>178</epage><pages>171-178</pages><issn>1868-6974</issn><eissn>1868-6982</eissn><abstract>Background
The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is extremely poor and the recurrence rate after curative operation is very high. There is no standard treatment to prevent recurrence of ICC. In this study, we investigated the clinical utilization of a dendritic cell vaccine plus activated T-cell transfer in an adjuvant setting for postoperative ICC.
Methods
36 patients with ICC were vaccinated at least 3 times with autologous tumor lysate pulsed dendritic cells plus ex-vivo activated T-cell transfer. The 5-year progression-free survival (PFS) and overall survival (OS) were measured and compared with those of 26 patients who received the curative operation alone as a concurrent control. The registration number was UMIN000005820.
Results
The median PFS and OS were 18.3 and 31.9 months in the patients receiving adjuvant immunotherapy and 7.7 and 17.4 months in the group receiving surgery alone (
p
= 0.005 and 0.022, respectively). In the treated group, patients whose skin reactions were 3 cm or more at the vaccine site showed dramatically better prognosis (PFS
p
< 0.001, OS
p
= 0.001).
Conclusions
A postoperative dendritic cell vaccine plus activated T-cell transfer would be a feasible and effective treatment for preventing recurrence and achieving long-term survival in ICC patients.</abstract><cop>Japan</cop><pub>Blackwell Publishing Ltd</pub><pmid>21874278</pmid><doi>10.1007/s00534-011-0437-y</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1868-6974 |
| ispartof | Journal of hepato-biliary-pancreatic sciences, 2012-03, Vol.19 (2), p.171-178 |
| issn | 1868-6974 1868-6982 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_917155859 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Abdominal Surgery adjuvant therapy Adoptive Transfer - methods Aged Bile Duct Neoplasms - immunology Bile Duct Neoplasms - therapy Bile Ducts, Intrahepatic cancer vaccine Cancer Vaccines - therapeutic use Cholangiocarcinoma - immunology Cholangiocarcinoma - therapy dendritic cell Dendritic cells Dendritic Cells - immunology Female Gastroenterology Hepatology Humans immunotherapy intrahepatic cholangiocarcinoma Liver Neoplasms - immunology Liver Neoplasms - therapy Lymphocyte Activation Male Medical prognosis Medicine Medicine & Public Health Middle Aged Original Article Ovarian cancer Postoperative Care - utilization Prospective Studies recurrence Surgical Oncology T-Lymphocytes - immunology Treatment Outcome Vaccines |
| title | Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A45%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20utilization%20of%20postoperative%20dendritic%20cell%20vaccine%20plus%20activated%20T-cell%20transfer%20in%20patients%20with%20intrahepatic%20cholangiocarcinoma&rft.jtitle=Journal%20of%20hepato-biliary-pancreatic%20sciences&rft.au=Shimizu,%20Koichi&rft.date=2012-03&rft.volume=19&rft.issue=2&rft.spage=171&rft.epage=178&rft.pages=171-178&rft.issn=1868-6974&rft.eissn=1868-6982&rft_id=info:doi/10.1007/s00534-011-0437-y&rft_dat=%3Cproquest_cross%3E917155859%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1711583644&rft_id=info:pmid/21874278&rfr_iscdi=true |